CMANY
VIVO

Capital Management Associates (New York)’s Meridian Bioscience Inc VIVO Stock Holding History

Capital Management Associates (New York)’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-15,000
Closed -$327K – 144
2014
Q1 		$327K Hold
15,000
– – 0.47% 109
2013
Q4 		$398K Hold
15,000
– – 0.59% 87
2013
Q3 		$354K Hold
15,000
– – 0.54% 94
2013
Q2 		$322K Buy
+15,000
New +$323K 0.53% 96

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
PIM
Perkins Investment Management Chicago, Illinois $8.09B AUM 25.47% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Capital Management Associates (New York)'s VIVO Position: Q2 2014 in Review

Capital Management Associates (New York) sold out of Meridian Bioscience Inc (VIVO) in Q2 2014, closing a stake of 15,000 shares — an estimated $327K sold.

Capital Management Associates (New York) first reported a position in VIVO in Q2 2013 and held it in 4 quarters. The position peaked at $398K in Q4 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q2 2014.

  • Capital Management Associates (New York) reported no remaining Meridian Bioscience Inc position as of Q2 2014 after selling out during the quarter.
  • Capital Management Associates (New York) sold 15,000 Meridian Bioscience Inc shares in Q2 2014, an estimated $327K.
  • Capital Management Associates (New York) first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 4 quarters.
  • Capital Management Associates (New York)'s Meridian Bioscience Inc position peaked at $398K in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2014.

Based on Capital Management Associates (New York)'s 13F filing for Q2 2014, filed 6 Aug 2014.